Emerging Threats: Multidrug Resistance and Clinical Challenges of Acinetobacter spp. in Modern Healthcare

Background: Multidrug-resistant (MDR) bacteria, including Acinetobacter baumannii, have increased in healthcare systems, particularly in the Middle East. This bacterium is notoriously resistant to various medications, complicating disease therapy. The proliferation of XDR bacteria and the decline of effective antibiotics threaten patient safety and healthcare efficiency.Objectives: This study addresses the issues associated with MDR Acinetobacter baumannii in hospitals, especially in the Middle East. It examines the bacterium's epidemiology, molecular resistance mechanisms, clinical problems, and innovative treatment approaches. The research employs novel epidemiological data, molecular insights, and enhanced infection control strategies to comprehend the evolution of this issue and its management.Methods: We conducted a comprehensive study by searching PubMed, Scopus, and Web of Science for research published from ۲۰۱۰ to ۲۰۲۴. The investigation identified Middle Eastern research regarding the prevalence, resistance mechanisms, clinical care, and patient outcomes of MDR Acinetobacter baumannii. This study offers a comprehensive perspective on the escalating threat posed by this disease and its ramifications for regional healthcare professionals through the integration of qualitative and quantitative data.Results: Carbapenem-resistant Acinetobacter baumannii is common in ۶۰–۷۰% of Middle Eastern intensive care units and kills ۴۰–۵۰%. OXA-type carbapenemases, ESBLs, MBLs, efflux pump overexpression, target site changes, and biofilm formation make the bacterium resistant. We also found novel resistance determinants including bla_OXA-۲۳۵ and regulatory gene alterations like adeRS. Overcrowded hospitals, long stays, antibiotic overuse, and poor infection control aggravate this issue. However, these issues are being fixed. Modern molecular diagnosis, ultraviolet disinfection, and genetic surveillance reduce these diseases.Conclusions: Increasing MDR Acinetobacter baumannii prevalence in the Middle East presents a difficult challenge that requires a coordinated, multidisciplinary approach. This pathogen's hazards can be reduced by improved antimicrobial stewardship, infection control, regional surveillance, and therapeutic development.

کلیدواژه ها:

MDR Acinetobacter baumannii ، Multidrug resistance ، middle east ، Carbapenem Resistance ، novel therapeutics